David Drutz, Director at Altimmune, Inc. (ALT), bought 1,200 shares at $4.50 ($5K) on 2022-05-24, disclosed to the SEC on 2022-05-25.
Open-market purchase of $5k ALT by Director. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade C.
Nothing distinguishes this filing.
| Filing → |
| ALT | BUY | 2023-03-27 | $38K | — | Filing → |
| ALT | BUY | 2022-06-16 | $8K | — | Filing → |
| ALT | BUY | 2017-08-24 | $22K | — | Filing → |